Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antacid Activity of Z0063 vs Gaviscon in Healthy Adults
NCT03069963Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Z0063 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of time at which the intragastric pH is at least equal to or greater than 4. Started Feb 2017; status: completed.
02
Drugs
Z0063
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03069963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069963.